Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant
Sign Up to like & getrecommendations! Published in 2017 at "Regulatory Toxicology and Pharmacology"
DOI: 10.1016/j.yrtph.2017.03.006
Abstract: &NA; Suvorexant (Belsomra®) is a dual orexin receptor antagonist approved for the treatment of insomnia. Because of its pharmacology within the central nervous system, intended therapeutic indication, and first‐in‐class status, an assessment of suvorexant abuse… read more here.
Keywords: suvorexant; receptor antagonist; pharmacology; assessment ... See more keywords
736 Evaluation of suvorexant for trauma-related insomnia
Sign Up to like & getrecommendations! Published in 2021 at "Sleep"
DOI: 10.1093/sleep/zsab072.733
Abstract: Finding medication treatment that improves sleep disturbances with posttraumatic stress disorder (PTSD) has challenged the field of psychopharmacology with debate regarding the desirable profile of effects on sleep physiology. Evidence for fragmentation of REM sleep… read more here.
Keywords: group; related insomnia; trauma related; trauma ... See more keywords